[go: up one dir, main page]

MXPA03010991A - Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico. - Google Patents

Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico.

Info

Publication number
MXPA03010991A
MXPA03010991A MXPA03010991A MXPA03010991A MXPA03010991A MX PA03010991 A MXPA03010991 A MX PA03010991A MX PA03010991 A MXPA03010991 A MX PA03010991A MX PA03010991 A MXPA03010991 A MX PA03010991A MX PA03010991 A MXPA03010991 A MX PA03010991A
Authority
MX
Mexico
Prior art keywords
subject
composition
cox
inhibitor
skin
Prior art date
Application number
MXPA03010991A
Other languages
English (en)
Inventor
Gokhale Rajeev
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA03010991A publication Critical patent/MXPA03010991A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a una composicion farmaceutica que se puede liberar dermicamente que comprende al menos, un farmaco o profarmaco del mismo, inhibidor de la ciclooxigenasa-2 (COX-2) selectivo, solubilizado en un portador farmaceuticamente aceptable que comprende un alcohol monohidrico de bajo peso molecular, y presenta una velocidad de permeacion en la piel del agente terapeutico al menos, igual a aquella presentada por una solucion de referencia del agente terapeutico en etanol acuoso al 70%. Un metodo para efectuar suministro objetivo de un farmaco inhibidor de COX-2 a un sitio de dolor y/o inflamacion en un sujeto, comprende administrar topicamente tal composicion a la piel del sujeto, preferiblemente en un lugar superyacente o adyacente al sitio del dolor y/o inflamacion. Un metodo para efectuar el tratamiento sistemico de un sujeto que tiene un trastorno mediado por COX-2, que comprende administrar transdermicamente tal composicion, preferiblemente, poniendo en contacto la composicion con el area de la piel del sujeto, no mayor de 400 cm.
MXPA03010991A 2001-05-31 2002-05-30 Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico. MXPA03010991A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29483801P 2001-05-31 2001-05-31
US35075601P 2001-11-13 2001-11-13
PCT/US2002/017067 WO2002096435A2 (en) 2001-05-31 2002-05-30 Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol

Publications (1)

Publication Number Publication Date
MXPA03010991A true MXPA03010991A (es) 2004-02-27

Family

ID=26968778

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010991A MXPA03010991A (es) 2001-05-31 2002-05-30 Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico.

Country Status (25)

Country Link
US (1) US20030161867A1 (es)
EP (1) EP1404345A2 (es)
JP (1) JP2004532871A (es)
KR (1) KR20040033286A (es)
CN (1) CN1547474A (es)
AP (1) AP2003002922A0 (es)
BR (1) BR0210104A (es)
CA (1) CA2448627A1 (es)
CO (1) CO5640125A2 (es)
CR (1) CR7173A (es)
CZ (1) CZ20033241A3 (es)
EA (1) EA200301200A1 (es)
EC (1) ECSP034869A (es)
HU (1) HUP0600294A2 (es)
IL (1) IL159100A0 (es)
IS (1) IS7055A (es)
MA (1) MA27030A1 (es)
MX (1) MXPA03010991A (es)
NO (1) NO20035325D0 (es)
OA (1) OA12613A (es)
PL (1) PL367337A1 (es)
SK (1) SK14762003A3 (es)
TN (1) TNSN03127A1 (es)
WO (1) WO2002096435A2 (es)
ZA (1) ZA200309298B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4283507B2 (ja) * 2002-08-02 2009-06-24 久光製薬株式会社 経皮投与用貼付剤
US20040127531A1 (en) * 2002-11-21 2004-07-01 Lu Guang Wei Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor
US20040126415A1 (en) * 2002-11-21 2004-07-01 Lu Guang Wei Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor
US20050020658A1 (en) * 2002-11-21 2005-01-27 Katsuyuki Inoo Selective cyclooxygenase-2 inhibitor patch
OA13018A (en) * 2003-01-23 2006-11-10 Shire Holings Ag Formulation and methods for the treatment of thrombocythemia.
BRPI0415111A (pt) * 2003-10-08 2006-11-28 Novartis Ag composição farmacêutica que compreende o ácido 5-metil-2-( 2`-cloro-6`-fluoroanilino) fenilacético
WO2005044227A1 (en) * 2003-11-05 2005-05-19 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
JP2008526963A (ja) * 2005-01-14 2008-07-24 リポ ケミカルズ インコーポレイテッド 過度に色素沈着した皮膚を処置するための組成物および方法
PE20061303A1 (es) * 2005-03-30 2006-12-07 Astion Dev As Composicion farmaceutica que comprende oxaprozina
EP1890687B1 (en) * 2005-06-14 2008-09-17 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable pharmaceutical gel of diclofenac sodium
US20120040809A1 (en) 2010-08-11 2012-02-16 Formicola Thomas M Stretch-Out Roll Up Bar
US20070243275A1 (en) * 2006-04-13 2007-10-18 Gilbard Jeffrey P Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
FR2905601A1 (fr) * 2006-09-11 2008-03-14 Innoderm Sarl Utilisation de derives oleiques comme methode et composition favorisant la penetration cutanee des actifs contenus dans les compositions cosmetiques, pharmaceutiques ou dermatologiques.
CN101588791A (zh) 2006-10-17 2009-11-25 纽沃研究公司 双氯芬酸凝胶
US7910597B2 (en) 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
HU227970B1 (en) * 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
DE102007034976A1 (de) 2007-07-26 2009-01-29 Bayer Healthcare Ag Arzneimittel zur transdermalen Anwendung bei Tieren
CA2730787A1 (en) 2008-07-16 2010-01-21 David M. Cohen Topical drug delivery system
EA019846B1 (ru) 2008-10-20 2014-06-30 Юнилевер Нв Противомикробная композиция, содержащая тимол и терпинеол, и ее применение
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
AU2010242866B2 (en) 2009-05-01 2014-09-25 Medtech Products Inc. Cleanser compositions and methods for using the same
CA2801143C (en) 2009-09-24 2017-09-26 Unilever Plc Disinfecting agent comprising eugenol, terpineol and thymol
WO2011041609A2 (en) * 2009-09-30 2011-04-07 Nuvo Research Inc. Topical formulations
EP2485730A1 (en) 2009-10-09 2012-08-15 Nuvo Research Inc. Topical formulation comprising etoricoxib and a zwitterionic surfactant
EP2575813A1 (en) * 2010-05-28 2013-04-10 Nuvo Research Inc. Topical etoricoxib formulation
BR112012029746A2 (pt) * 2010-05-31 2016-08-09 Unilever Nv composição para tratamento da pele, método para fornecer um efeito microbicida para pele e uso de uma combinação
JP2012020991A (ja) * 2010-06-16 2012-02-02 Takasago Internatl Corp 経皮吸収促進剤、及びこれを含有する皮膚外用製剤
EP2648681B1 (en) 2010-12-07 2015-01-07 Unilever N.V. An oral care composition
CN103269687B (zh) * 2011-01-04 2016-09-14 伊斯塔制药公司 贝托斯汀组合物
EP2691076A1 (en) * 2011-03-31 2014-02-05 Evocutis plc Usnic acid topical formulation
SG11201400977QA (en) * 2011-10-05 2014-04-28 Douglas Pharmaceuticals Ltd Pharmaceutical methods and topical compositions containing acitretin
IN2014MN00808A (es) 2011-11-03 2015-09-04 Unilever Plc
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201206486D0 (en) * 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045965B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
WO2014157727A1 (ja) * 2013-03-29 2014-10-02 株式会社ＡｓｋＡｔ 眼疾患治療剤
CN105848730B (zh) * 2013-12-24 2019-12-13 宝洁公司 提供增强的护肤活性物质渗透的化妆品组合物和方法
HUE048374T2 (hu) * 2014-11-10 2020-07-28 Achelios Therapeutics Inc Permetezhetõ fájdalomcsillapító készítmények
PT3316857T (pt) 2015-06-30 2021-11-03 Sequessome Tech Holdings Limited Composições multifásicas
CN105663032A (zh) * 2016-02-23 2016-06-15 青岛科技大学 一种维他昔布软膏剂的制备方法
CN106267218A (zh) * 2016-10-18 2017-01-04 华北理工大学 4‑萜品醇脂肪酸酯衍生物及其应用和制备方法
KR102042456B1 (ko) * 2018-03-22 2019-11-08 크리스탈지노믹스(주) 경피흡수제제
CN112203643A (zh) * 2018-05-31 2021-01-08 国立大学法人九州大学 经皮吸收制剂
RU2685436C1 (ru) * 2018-06-22 2019-04-18 ЗАО "ФармФирма "Сотекс" Трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей
CN115916183A (zh) * 2020-01-10 2023-04-04 布里奥里生物技术公司 含有罗非昔布的局部用组合物及其制备和使用方法
KR20220001170A (ko) 2020-06-29 2022-01-05 김종림 앙카볼트
US12250946B2 (en) 2020-10-20 2025-03-18 Korea University Research And Business Foundation Antifungal composition having excellent antifungal activity even at low temperature
KR102619716B1 (ko) * 2020-10-20 2023-12-29 고려대학교 산학협력단 저온에서도 우수한 항균활성을 갖는 항진균용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3526887B2 (ja) * 1993-04-23 2004-05-17 帝國製薬株式会社 消炎鎮痛外用貼付剤
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
RO118200B1 (ro) * 1995-05-25 2003-03-28 Gd Searle & Co Chicago Procedeu pentru obtinerea (3-haloalchil-1h-pirazol-1-il)-arilsulfonamidelor
US5981576A (en) * 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
TR199802049T2 (xx) * 1996-04-12 1999-01-18 G.D.Searle & Co. COX-2 Inhibit�rlerinin �nilac� olarak s�bstit�e edilmi� benzens�lfonamid t�revleri.
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
GB2340751B (en) * 1998-08-12 2003-11-05 Edko Trading Representation Pharmaceutical compositions
CA2348979A1 (en) * 1998-11-02 2000-05-11 Merck & Co., Inc. Method of treating migraines and pharmaceutical compositions
DE60017831T3 (de) * 1999-01-14 2009-12-17 Noven Pharmaceuticals, Inc., Miami Dermale zusammensetzungen
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AU5460800A (en) * 1999-06-02 2000-12-18 Aviana Biopharm Pharmaceutical transdermal compositions
IN191512B (es) * 2000-01-21 2003-12-06 Panacea Biotech
US20020077328A1 (en) * 2000-07-13 2002-06-20 Fred Hassan Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain
IN191090B (es) * 2000-08-29 2003-09-20 Ranbanx Lab Ltd
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability

Also Published As

Publication number Publication date
EP1404345A2 (en) 2004-04-07
WO2002096435A2 (en) 2002-12-05
IL159100A0 (en) 2004-05-12
WO2002096435A3 (en) 2003-05-01
US20030161867A1 (en) 2003-08-28
CZ20033241A3 (cs) 2004-08-18
AP2003002922A0 (en) 2003-12-31
CA2448627A1 (en) 2002-12-05
ZA200309298B (en) 2004-05-12
OA12613A (en) 2006-06-09
SK14762003A3 (sk) 2004-08-03
IS7055A (is) 2003-11-27
CO5640125A2 (es) 2006-05-31
TNSN03127A1 (fr) 2005-12-23
EA200301200A1 (ru) 2004-06-24
NO20035325D0 (no) 2003-11-28
BR0210104A (pt) 2004-06-08
PL367337A1 (pl) 2005-02-21
HUP0600294A2 (en) 2007-02-28
ECSP034869A (es) 2004-07-23
CN1547474A (zh) 2004-11-17
MA27030A1 (fr) 2004-12-20
KR20040033286A (ko) 2004-04-21
JP2004532871A (ja) 2004-10-28
CR7173A (es) 2004-04-22

Similar Documents

Publication Publication Date Title
MXPA03010991A (es) Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico.
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
AU2023266295A1 (en) Therapeutic topical compositions of apremilast
KR102658565B1 (ko) 신체 표면 장애의 치료를 위한 장치
AR032556A1 (es) Medicamento de accion inmediata para el tratamiento de la disfuncion sexual
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
ATE533472T1 (de) Flüssige cannabinoid-formulierungen zur verabreichung an die schleimhäute
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
TR200500745T2 (tr) Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
UA88270C2 (ru) Фармацевтический препарат и его применение для профилактики удара, диабета
AR033688A1 (es) Composicion parenteral reconstituible
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
PT1150704E (pt) Melagatran para o tratamento da inflamacao
WO2005065648A3 (en) Novel drug compositions and dosage forms of topiramate
AR046146A1 (es) Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso
NO20021437D0 (no) Fremgangsmate til forebyggelse av kolorektal kreft
HN2001000038A (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
WO2003066806A3 (en) Therapeutic use of aziridino compounds
UY28579A1 (es) Formulaciones farmacéuticas transdermicas
AR012872A1 (es) Uso del mometanosulfonato del acido (e)-alfa-[2-n-butil-1-[(carboxifenil)metil]-1-h-imidazol-5- il]metilen-2-tiofenpropionico para la fabricacion de un medicamento ycomposicion farmaceutica que lo comprende para tratar hipertension sistolica aislada.